Short course of low-dose heparin after childbirth to prevent blood clots
Tests low-dose heparin against no treatment for venous thromboembolism after delivery.
Key facts
- Who runs it
- Marc Blondon
- Where
- Switzerland9 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 9,200 people, planned
- Started
- 15 Oct 2025
- Expected to end
- Aug 2030
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Low-dose low-molecular-weight heparin
- Record updated
- 6 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women who have just given birth and have a higher chance of blood clots. It compares a short course of low-dose LMWH (a blood thinner) with no treatment.
- Age
- 18 years and older
- Sex
- Women only
- Disease stage
- Just after giving birth, with at least 1 major or at least 2 minor risk factors for clots. Major: emergency cesarean section, pre-pregnancy BMI ≥35kg/m2, known low-risk thrombophilia, pre-eclampsia, pre-term delivery, infection around birth, baby's growth restriction in the womb, pregnancy loss. Minor: age ≥35 years, pre-pregnancy BMI 30.0-34.9kg/m2, current smoking, planned cesarean section, heavy bleeding after birth, being immobile before birth.
- Earlier treatment
- People who have already had 2 or more doses of LMWH after giving birth cannot join.
- Biomarker or test result
- Known low-risk thrombophilia counts as a major risk factor: heterozygous factor V Leiden or heterozygous G20210 prothrombin mutation.
Main reasons for not taking part
- 2 or more doses of LMWH after giving birth
- Any reason to need full-dose blood-thinning treatment
- A high risk of blood clots after birth
- A higher risk of bleeding
- A reason you cannot take heparin
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Major risk factors: Emergency cesarean section ; Pre-pregnancy BMI ≥35kg/m2 ; Known low-risk thrombophilia (heterozygous factor V Leiden; heterozygous G20210 prothrombin mutation) ; Pre-eclampsia ; Pre-term delivery ; Peripartum systemic infection ; Intra-uterine growth restriction ; Pregnancy loss
- Minor risk factors: Age ≥35 years ; Pre-pregnancy BMI 30.0-34.9kg/m2 ; Current smoking ; Elective cesarean section ; Postpartum hemorrhage ; Antenatal immobility
Who cannot take part
- An increased bleeding risk
- ≥2 doses of postpartum LMWH
- Any indication for therapeutic anticoagulation
- A high-risk of postpartum VTE
- A contra-indication to heparin
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are:
Read full original descriptionShow less
* compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery? * compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.
The 2 groups in the trial
- Low-molecular-weight heparinTreatment being tested
Treatment: Low-dose low-molecular-weight heparin
- No treatmentNo study treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis: a Pragmatic, Multi-center, Open-label Randomized Controlled Study
- Plain-language title
- Short course of low-dose heparin after childbirth to prevent blood clotsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 6 October 2026